Document Type

Journal Article

Publisher

Austin Publishing Group

School

School of Medical Sciences

RAS ID

21734

Comments

Originally published as: Martins, I. J. (2016). Drug therapy for obesity with anti-aging genes modification. Annals of Obesity & Disorders, 1(1). Original article available here

Abstract

Nutritional regulation and drug therapy has been the focus of the current obesity epidemic in various countries in the world. Epigenetics is the major mechanism for the development of insulin resistance and obesity with unhealthy diets, oxidative stress and environmental factors relevant to alterations in gene expression with effects on mitochondrial biogenesis, adipose tissue lipid metabolism and energy expenditure. Anti-aging genes are involved in the regulation of adipogenesis with increased sensitivity to anti-aging gene dysfunction associated with adipocyte-neuron interactions compared to other cells. Unhealthy diets downregulate adipocyte anti-aging genes associated with the development of Non Alcoholic Fatty Liver Disease (NAFLD) with relevance to regulation of drug metabolism and delayed pharmacokinetics in the body. Evaluation by different methods and techniques to quantify and characterize adiposity has been undertaken to obtain a better understanding of adipocyte metabolism in obesity but adipocyte analysis is now required to determine adipose tissue anti-aging gene expression. Effective drug treatment programs cannot be determined in individuals with obesity with defective adipocyte tissue gene expression. New drug development needs to be carefully interpreted in relation to nutritional intake with drug safety concerns/adverse effects relevant to adipogenesis and NAFLD in obesity.

Access Rights

Open access

Creative Commons License

Creative Commons Attribution 4.0 License
This work is licensed under a Creative Commons Attribution 4.0 License.

Share

 
COinS